Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ADvance II: A 12-month Double-blind, Randomized, Controlled Study to Evaluate the Safety and Efficacy of Deep Brain Stimulation of the Fornix (DBS-f) in Patients With Mild Probable Alzheimer's Disease

NCT03622905 is registered in ClinicalTrials.gov with Functional Neuromodulation Ltd as lead sponsor.

NCT NCT03622905
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03622905 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ADvance II: A 12-month Double-blind, Randomized, Controlled Study to Evaluate the Safety and Efficacy of Deep Brain Stimulation of the Fornix (DBS-f) in Patients With Mild Probable Alzheimer's Disease
Lead sponsor
Functional Neuromodulation Ltd
Phase
Not applicable
Overall status
Completed
Start date
August 1, 2019
Completion date
February 19, 2024
Enrollment
74 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease